CD274 and neoplasm: In addition to several biomarkers, including programmed cell death ligand-1 (PD-L1) [7], tumor mutational burden (TMB) [8], DNA damage repair [9], and tertiary lymphoid structures [10] used to predict ICIs efficacy, cancer-associated anemia has been identified as a risk factor that reduces ICIs efficacy [11, 12].